AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

KLRA · NASDAQ · Biotechnology

Kailera Therapeutics (KLRA)

Develops injectable and oral obesity medicines outside Greater China under a Hengrui license.

$16.01

Pre-market+0.17 (+1.07%)

At close$15.84(−3.47%)

Watchlist

In millions of USD, except per-share figures

In millions	Q1 FY26Mar 2026	Q2 FY26Jun 2026
	85	121
Research & development	71	101
	14	20
General & administrative	14	20
Operating income	−85	−121
	6	10
Interest income	6	10
Other non-operating income	0	−10
Income before tax	−79	−111
Net income from continuing operations	−79	−111
Net income	−79	−111
EPS, basic	−$0.67	−$1.09
EPS, diluted	−$0.67	−$1.09
Weighted average shares, basic	118	102
Weighted average shares, diluted	118	102
EBITDA	−85	−111
Depreciation & amortization	0	0
EBIT	−85	−111